Apotex has settled patent litigation over Vascepa with Amarin, providing the generics firm with a guaranteed launch date in 2029.
Apotex has settled with Amarin over its generic version of the originator’s Vascepa (icosapent ethyl) in the US, providing a guaranteed launch date of 9 August 2029.
The date matches that agreed by Amarin with Teva in a separate settlement deal struck two years ago, in...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
